ENTERA BIO LTD
NASDAQ: ENTX (Entera Bio Ltd.)
Kemas kini terakhir: 1 jam lalu2.95
0.03 (1.03%)
| Penutupan Terdahulu | 2.92 |
| Jumlah Dagangan | 143,687 |
| Harga / Jualan (P/S) | 1.43 |
| Harga / Buku (P/B) | 68.99 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -6,102.38% |
| EPS Cair (TTM) | -0.260 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.14% |
| Nisbah Semasa (MRQ) | 13.07 |
| Aliran Tunai Operasi (OCF TTM) | -6.36 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -11.17 M |
| Pulangan Atas Aset (ROA TTM) | -39.60% |
| Pulangan Atas Ekuiti (ROE TTM) | -71.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Entera Bio Ltd. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 24.42% |
| % Dimiliki oleh Institusi | 22.17% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Knoll Capital Management, Llc | 30 Jun 2026 | 5,881,879 |
| Bvf Inc/Il | 30 Jun 2026 | 2,425,000 |
| Hightower Advisors, Llc | 30 Jun 2026 | 74,573 |
| Signature Estate & Investment Advisors Llc | 30 Jun 2026 | 47,328 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |